A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

NCT ID: NCT05777993

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: PHASE4
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-06
• Study Completion Date: 2029-08-31

Brief Summary

The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.

Detailed Description

Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.

Conditions

Pyruvate Kinase Deficiency; Anemia, Hemolytic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Mitapivat

Participants will receive mitapivat of 5, 20 or 50 milligrams (mg), orally, twice daily (BID), based on the last dose received by the participants in the antecedent study. Mitapivat will be administered from Day 1 up to end of treatment period of this study.

Group Type: EXPERIMENTAL

Mitapivat

Intervention Type: DRUG

Tablets

Interventions

Mitapivat

Tablets

Intervention Type: DRUG

Other Intervention Names

AG-348; Mitapivat sulfate; PYRUKYND®

Eligibility Criteria

Inclusion Criteria

• Has completed an Agios-sponsored adult pyruvate kinase (PK) deficiency study of mitapivat within 1 day of enrollment in this rollover study;
• Is unable to obtain mitapivat treatment due to country regulations or lack of commercial access;
• Was deriving clinical benefit from mitapivat treatment at the completion of the antecedent study, in the opinion of the Investigator;
• For women of childbearing potential, must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
• Written informed consent from the participant before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study;
• Agrees not to participate in other interventional clinical studies, including other studies of mitapivat, during participation in this study.

Exclusion Criteria

• Has discontinued treatment with mitapivat before completing the antecedent study;
• Known allergy or other contraindication to mitapivat or its inactive ingredients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, Opadry II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD&C Blue #2]);
• Any medical, hematologic, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study also excluded are:

• Participants who are institutionalized by regulatory or court order
• Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Agios Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

McMaster Centre for Transfusion Medicine McMaster University

Hamilton, Ontario, Canada

Tohoku University Hospital

Sendai, Miyagi, Japan

Kyoto Katsura Hospital

Kyoto, , Japan

Toho University - Omori Medical Center

Ōta-ku, , Japan

Countries

Canada; Japan

Other Identifiers

AG348-C-025

Identifier Type: -

Identifier Source: org_study_id